Matt’s routine health check found a so-called ‘old man’s disease’. He’s 45

Though he is young to be diagnosed with the type of cancer, vigilance and understanding the risks have changed the course of ...

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment ...
The Manila Times

Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...
The Nation Newspaper

Medical outlet expands critical care with N200m ICU facility

Avon Medical Practice has expanded its critical care capacity with launch of an Intensive Care Unit (ICU). The N200 million ...

I’ve been a health editor for a decade, these are the 2026 wellness trends you need to know

I’ve worked at the forefront of health and wellness for a long time and I’ve seen it all, this is what’s coming in 2026 – the ...

PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID Program

The company confirmed the publication of its successful clinical case series in Frontiers in Immunology, a peer-reviewed scientific journal, and received confirmation from the U.S. Food and Drug ...
PharmiWeb

Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder

Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that the first participant has been dosed in the ...
Le Lézard

EMED PROVIDES ACCESS TO FDA-APPROVED WEGOVY® PILL THROUGH ITS TRUSTED, CLINICALLY GUIDED MODEL OF CARE

Med Population Health, the leading digital health platform for GLP-1/GIP population health management, today announced it has been named a Novocare Recognized Care Provider delivering access to the ...
Investor's Business Daily on MSN

Arrowhead says its gene silencer doubled Zepbound's weight loss

Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide ...

Genprex, Inc.: Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted ...
The Independent on MSN

These are the 2026 wellness trends to know, according to experts

I’ve been a health editor for a decade, these are the 2026 wellness trends you need to know - I’ve worked at the forefront of ...
Santé log

Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been enrolled in its new Phase 2b clinical trial ( CAPTAIN-T2D, NCT07296484) ...